Subtle Medical's FDA-cleared AI tool, SubtlePET will be integrated with Telix’s prostate-specific membrane antigen (PSMA)-PET agent, Illuccix (68Ga-PSMA-11), to facilitate faster PET scans and improve workflow efficiency in imaging facilities.
SubtlePET, designed to speed up PET scans by as much as 75% without diminishing image quality, uses deep-learning algorithms to optimize imaging processes. The tool’s reduced scan time can significantly decrease patient waiting and motion requirements, potentially improving patient comfort and throughput. By allowing for more rapid scans, SubtlePET offers imaging facilities a pathway to enhance their operational efficiency and extend scanner utility, regardless of make or model.
“This partnership allows us to incorporate an innovative AI product into the Illuccix value proposition for our customers and the patients they serve,” said Kevin Richardson, Telix’s chief executive officer of precision medicine. “The combination of Illuccix and SubtlePET will strengthen Telix’s AI toolkit, building Illuccix’s reputation as a best-in-class PSMA-PET imaging agent for accuracy, reliability, quality, and operational excellence in the U.S.”
The partnership will first launch with Illuccix in the U.S., with plans to expand into North America and the European Union (excluding France and French-speaking Belgium). Additionally, pending regulatory approval, Telix may extend the use of SubtlePET to other PET tracers in its portfolio.
Telix Pharmaceuticals, headquartered in Melbourne, Australia, specializes in radiopharmaceuticals for diagnostics and therapy, while Subtle Medical focuses on AI solutions to enhance medical imaging efficiency.
